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Despite huge advances in medicine, glioblastoma multiforme (GBM) remains a highly lethal, fast-growing tumour
that cannot be cured by currently available therapies. However, extracranial and extraneural dissemination of GBM
is extremely rare, but is being recognised in different imaging studies. To date, the cause of the GBM metastatic
spread still remains under discussion. It probably develops at the time of intracranial progression following a
surgical procedure. According to other hypothesis, the metastases are a consequence of spontaneous tumour
transdural extension or haematogenous dissemination. We present a case of a 59-year-old woman with
symptomatic leptomeningeal and intramedullary metastases of GBM who has been previously surgically treated
with primary subtotal resection and underwent a repeated surgery during adjuvant radiotherapy and
chemotherapy with temozolomide. Today, the main goal of surgery and chemoradiotherapy is to prevent
neurologic deterioration and improve health-related quality of life. With this paper, we want to present this rare
entity and emphasise the importance of a multidisciplinary approach, a key function in the management of brain
tumour patients. The prognosis is still very poor although prolongation of survival can be obtained. Finally,
although rare, our case strongly suggests that clinicians should be familiar with the possibility of the extracranial
spread of GBM because as treatment improvements provide better control of the primary tumour and improving
survival, metastatic disease will be increasingly encountered.
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Glioblastoma multiforme (GBM) is the most common
primary malignancy of the central nervous system
(CNS) in adults. Macroscopically evident and symptom-
atic spinal metastases occur rarely, in up to 2% to 5% of
patients [1,2]. Spread or dissemination within the
neuraxis [3] is commoner than spread to other areas like
the vertebral body and peritoneum which have also been
reported [4,5]. We present a rare case of symptomatic
spinal leptomeningeal and intramedullary metastases of
GBM in a patient who has been previously surgically
treated with primary subtotal resection and underwent a* Correspondence: josipjoachimgrah@yahoo.com
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reproduction in any medium, provided the orrepeated surgery during adjuvant radiotherapy and
chemotherapy with temozolomide.Case presentation
In June 2011, a 59-year-old white female presented with
headaches and right facial palsy of the central type. Mag-
netic resonance imaging (MRI) of the brain showed a le-
sion in the right frontal area. A right frontotemporal
craniotomy for the mass resection was performed. Intra-
operatively, a quite irregular and partially necrotic
tumour mass was noted. The pathohistology analysis
demonstrated marked nuclear pleomorphism, scattered
mitoses and vascular endothelial proliferation with ne-
crosis, consistent with the diagnosis of GBM (World
Health Organization (WHO) grade IV) (Figure 1A). The
patient had a good Karnofsky performance status (KPS
>70) without any aberration of cognitive functions. Sixd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Histopathological evaluation. Hematoxylin and eosin
(HE) histologic analysis revealed a highly cellular tumour tissue
composed of pleomorphic astroglial cells with hyperchromatic
nuclei, mitosis and glomeruloid vascular proliferation, which are a
classic histological features in glioblastoma multiforme (A, high-
power photomicrograph, original magnification, ×400). After 48Gy
chemoradiotherapy, previously treated glioblastoma shows
heterogeneos composition with area of coagulative necrosis and
hyalinized blood vesels. Nuclear pleomorphism of tumour cells
without mitosis were noted (B, high-power photomicrograph,
original magnification, ×400).
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vant radiotherapy (three-dimensional conformal external
beam radiotherapy (3D-CRT)) with concurrent chemo-
therapy (temozolomide 75 mg/m2 per day) with regular
daily administration of dexamethason 12 mg i.m. During
chemoradiotherapy (after 24 of 30 fractions), she under-
went an MRI examination due to exacerbation of the
neurological signs and tumour progression was noted
(Figure 2). A right frontotemporal recraniotomy was
performed with preoperative administration of Gliolan.
Using fluorescent light, a tumour that encompassed
arteria cerebri media and its branches in fissura Sylvii
were noted and a subtotal resection was performed. The
mass was firm and fixed with blood vessels. A histo-
pathological examination confirmed GBM (Figure 1B). Adecision to re-resect the tumour was made by the
neurosurgeon in consultation with other members of the
team, taking into consideration the good performance
status of the patient. Adjuvant radiotherapy and chemo-
therapy (temozolomide 75 mg/m2 per day) continued
with 16 Gy in eight fractions (total dose of 60 Gy in 30
fractions). Sequential chemotherapy with temozolomide
(150 to 200 mg/m2 for 5 days during each 28-day cycle)
was discontinued after two cycles because the patient
complained of back pain and proximal weakness in both
lower limbs with paraesthesia. MRI of the cervical spine
demonstrated enhancing cervical leptomeningeal metas-
tases on a level of C3 to C7. Additionally, on a T8 to
T10 level, MRI also revealed intramedullary metastases
with extensive contrast enhancement, central necrosis
and vasogenic oedema (Figure 3). A follow-up MRI of
the brain showed no significant intracranial changes.
Palliative radiotherapy to C3 to C6 and T8 to T10 with a
total dose of 30 Gy in 10 fractions was delivered because
at that point, the patient was still in good general condi-
tion. The palliative effects in terms of pain relief lasted
until the patient’s death 1 month after the diagnosis of
spinal metastases. The patient probably died as a result
of extracranial or intracranial disease progression (pre-
sumably both). No autopsy was performed as requested
by the family.
Discussion
Gliomas comprise a heterogeneous group of tumours
that differ in location within the CNS, in age and sex
distribution, in morphological features, in tendency to
progression, and in response to surgical and oncological
treatment. GBM remains the most aggressive of gliomas,
a collection of tumours developing from glial tissue or
their precursors, accounting for 12% to 15% of all intra-
cranial neoplasms [2]. First described by Rudolph Virchow
in 1863, it represents the most common tumour of the
cerebral hemispheres, usually occurring between the ages
of 40 and 60 years old. Genetic alterations such as point
mutations, loss of heterozygosity or excessive activation of
a particular genes are all reported in GBMs, but intrinsic
risk factors are currently unknown [6]. Evidence of associ-
ation with occupational risk factors, head injury or expos-
ure to electromagnetic fields is inconclusive. The incidence
in Europe and North America is two to three cases/
100,000 per year [7]. However, much less commonly, GBM
can affect the brainstem (especially in children) and the
spinal cord [8,9]. Clinically, gliomas are divided into four
grades; the most aggressive of these, grade IV or GBM, is
also the most common in humans. These tumours may de-
velop from lower-grade astrocytomas (WHO grade II) or
anaplastic astrocytomas (WHO grade III) (secondary
GBM), but more frequently they manifest de novo, without
any evidence of less malignant precursors (primary GBM)
Figure 2 Radiological evaluation of the brain. T1-weighted axial gadolinium-enhanced magnetic resonance image demonstrates an
enhancing tumour of the right frontal lobe (A). T2-weighted image demonstrates the same lesion as in the previous image, with notable tissue
edema (B). This finding is consistent with a high-grade glioblastoma. On fast fluid-attenuated inversion-recovery (FLAIR) MRI scan a zone of
edema is identified around the tumour demonstrating increased signal intensity (C, D).
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mal cells, which contribute to their heterogeneity and
variable outcome. Molecular studies and gene profiling po-
tentially allow for better classification of these tumours and
their division into different prognostic groups.
With the exception of brainstem gliomas, GBM has
the worst prognosis of any CNS malignancy, despite
multimodality treatment. The current standard of care for
glioblastoma is surgical resection of as much of the
tumour as is safe and possible, followed by postoperative
radiation therapy (focal irradiation at a dose of 2 Gy/frac-
tion given once daily 5 days per week over a period of 6
weeks, for a total dose of 60 Gy) and chemotherapy
(temozolomide at a dose of 75 mg/m2/day, given 7 days
per week from the first day of radiotherapy up to the last
day of radiotherapy, but for no longer than 49 days). After
a 4-week break, patients were then to receive up to sixcycles of temozolomide according to the standard 5-day
schedule every 28 days. [12]. To date, systemic delivery of
different chemotherapeutic agents to GBM has had
limited efficiency with significant side effects including
haematological toxicity, specifically thrombocytopenia and
neutropenia. Even under the best of circumstances, where
all of the tumour seen on MRI scan can be surgically
removed and patients are fully treated with radiochemo-
therapy, over 75% of patients die within 18 months and
essentially none attain long-term survival [13,14]. How-
ever, some progress is being made in the field of molecular
neuro-oncology, which involves an understanding of the
mutations and expression of genes that have been impli-
cated with GMB pathophysiology [15-23]. Such proce-
dures may be helpful to identify the tumour and they also
could facilitate therapy as potential vectors of treatment
[24,25]. The main objective is not only to generate more
Figure 3 Radiological evaluation of the spinal cord. MRI of the cervical spine demonstrated an enhancing cervical leptomeningeal metastases
(arrows) at the level C3 to C7. (A, T1-weighted image). Additionally, at the T8 to T10 level, MRI also revealed intramedullary metastases with
extensive contrast enhancement, central necrosis and vasogenic edema (arrows) (B, T1-weighted image) and C (T2-weighted image).
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cific types of different brain tumours. Finally, a genetic
profile could be the deciding factor in the diagnosis and
treatment for each patient individually, while best meeting
cost/benefit issues.
Notwithstanding all this, the treatment of GBM still re-
mains one of the most disappointing challenges in modern
oncology. A surgical cure for these brain tumours is virtu-
ally impossible to provide. The clinical course is deter-
mined by the biology of the tumour and response to
surgery, radiation and chemotherapy [26]. In our patient,
the treatment was multimodal and multidisciplinary,
based on cytoreductive surgery followed by chemotherapy
(temozolomide) and radiotherapy. As we know, surgical
intervention and radical resection are essential in the ini-
tial treatment while the extent of surgery can affect overall
patient survival [27-30]. When faced with evidence of re-
current or metastatic GBM, surgical intervention requires
identification of goals and a clear consideration of overall
prognosis, including all treatment side effects. In patients
with good KPS (>70) and without significant contraindica-
tions, surgery can improve neurological status and reduce
intracranial pressure. Repeated resection should only be
considered in patients with high preoperative KPS (>70)
or in those whose symptoms are secondary to mass effect
from superficial regions and whose lesions are in a
favourable brain location [30]. Radiological follow-up
should include brain/spinal MRI every 4 to 6 months afterthe cranial removal [31]. However, the efficacy of repeated
resection alone in cases of recurrent GBM remains con-
troversial due to a lack of randomized clinical trials. Some
studies showed that the median survival time after resec-
tion was 14 to 50 weeks [32-34].
As mentioned earlier, spinal or systemic GBM metas-
tases are very rare [1,2]. This could be because of patient
death before clinically detectable spreading or impedi-
ments to systemic egress. Spinal and dural metastases
should be commonly suspected in all patients with a his-
tory of intracranial GBM who complain about signs and
symptoms not explained by the primary lesion. The clin-
ical diagnosis of these conditions may be difficult, but is
possible with careful neurological examination directed
at radicular signs. Spinal MRI with contrast enhance-
ment has a leading diagnostic role in patients with ser-
ious spinal pathology and should be considered in the
presence of any clinical signs of spinal involvement
[35,36]. To date, the cause of the tumour spread still re-
mains under discussion. It probably develops at the time
of intracranial progression following a surgical proced-
ure. According to other hypothesis, spinal metastases
most likely occur as a result of cellular spread in the
subarachnoidal space or haematogenous dissemination
[2]. Any new onset of axial back pain or neurological
deficit of the extremities in patients with prior diagnosis
of GBM should indicate suspected spinal metastasis,
however rarely they may occur.
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very poor, regardless of the treatment modality used.
The survival of patients is approximately 2 to 3 months
[37,38]. Radiotherapy is the most common treatment
modality with 3 to 4 Gy per fraction to a total dose of
up to 40 Gy [39]. Radiotherapy may provide relief of
pain and some improvement in neurological function,
but no survival benefits. Systemic chemotherapy or in-
traventricular chemotherapy in combination with radio-
therapy has also not improved overall survival [40].
Surgery may enhance the risk of drop metastases, al-
though these have also been reported in patients who
have never had a surgical procedure [41].
Conclusion
Although merely a theoretical possibility in most cases,
reoperation of GBM during adjuvant radiochemotherapy
was still feasible in our patient. Today, the main object-
ive of chemoradiotherapy in patients with metastatic
GBM is to prevent neurologic deterioration and improve
health-related quality of life [26]. Researchers continue
to study the common characteristics of GBM and how
personalized and targeted treatments may be optimally
used. With this paper, we not only aim to present this
rare entity, but also to emphasise the importance of a
multidisciplinary approach, a key function in the man-
agement of tumour patients. Additionally, clinicians
should be familiar with the possibility of extracranial
spreading of GBM because as treatment improvements
provide better control of the primary tumour and im-
proving survival, metastatic disease will be increasingly
encountered.
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